Biotechnology company developing targeted protein degradation therapies for immune-inflammatory diseases.
Kymera Therapeutics, Inc. is a pioneering biopharmaceutical company specializing in the discovery and development of innovative small molecule therapeutics. The company's unique approach focuses on selectively degrading disease-causing proteins by leveraging the body's natural protein degradation system. This novel strategy aims to address a broad spectrum of diseases with significant unmet medical needs.
Kymera Therapeutics is actively advancing several promising programs in its pipeline. Among these is the IRAK4 program, currently undergoing Phase I clinical trials. This program targets immunology-inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis. Additionally, the company is developing the IRAKIMiD program specifically designed to treat MYD88-mutated diffuse large B cell lymphoma.
Furthermore, Kymera Therapeutics is advancing the STAT3 program, which holds potential for treating hematologic malignancies, solid tumors, autoimmune diseases, and fibrosis. The company's MDM2 program is also in development, focusing on hematological malignancies and solid tumors.
Founded in 2015 and headquartered in Watertown, Massachusetts, Kymera Therapeutics is at the forefront of innovative therapeutic approaches. By harnessing cutting-edge scientific insights, the company aims to transform the treatment landscape for patients facing serious and complex diseases globally.